PRIMOMED

Use of PRIMate MOdels to support translational MEDicine and advance disease modifying therapies for unmet medical needs

 Coordinatore AMAKEM NV 

 Organization address address: AGORALAAN GEBOUW ABIS BIOVILLE
city: DIEPENBEEK
postcode: 3590

contact info
Titolo: Dr.
Nome: Jack
Cognome: Veuskens
Email: send email
Telefono: 32496741166
Fax: 3211490209

 Nazionalità Coordinatore Belgium [BE]
 Totale costo 1˙602˙769 €
 EC contributo 1˙234˙000 €
 Programma FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs
 Code Call FP7-SME-2013
 Funding Scheme BSG-SME
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-01-01   -   2015-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    AMAKEM NV

 Organization address address: AGORALAAN GEBOUW ABIS BIOVILLE
city: DIEPENBEEK
postcode: 3590

contact info
Titolo: Dr.
Nome: Jack
Cognome: Veuskens
Email: send email
Telefono: 32496741166
Fax: 3211490209

BE (DIEPENBEEK) coordinator 320˙235.00
2    COMPLIX NV

 Organization address address: AGORALAAN BUILDING A-BIS
city: DIEPENBEEK
postcode: 3590

contact info
Titolo: Dr.
Nome: Thore
Cognome: Hettmann
Email: send email
Telefono: 3211286952

BE (DIEPENBEEK) participant 374˙599.00
3    MIND-NRG SA

 Organization address address: RUE DE JARGONNANT 2
city: GENEVE
postcode: 1207

contact info
Titolo: Mr.
Nome: Bertrand
Cognome: Damour
Email: send email
Telefono: 41793796118

CH (GENEVE) participant 354˙550.00
4    FAST FORWARD PHARMACEUTICALS BV

 Organization address address: YALELAAN 46
city: UTRECHT
postcode: 3584 CM

contact info
Titolo: Mr.
Nome: Mark
Cognome: De Boer
Email: send email
Telefono: 31654311946

NL (UTRECHT) participant 172˙616.00
5    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Ms.
Nome: Andrea
Cognome: Zeumann
Email: send email
Telefono: +49 89 1205 2723

DE (MUENCHEN) participant 6˙000.00
6    STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

 Organization address address: LANGE KLEIWEG 161
city: RIJSWIJK ZH
postcode: 2288 GJ

contact info
Titolo: Prof.
Nome: Bert
Cognome: T Hart
Email: send email
Telefono: 31152842691

NL (RIJSWIJK ZH) participant 6˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

ms    parkinson    smes    treatment    rock    il    modifying    primate       chronic    compounds    drug    diseases    inflammatory    unmet    disease    models    sme    medical    action    asthma    primomed   

 Obiettivo del progetto (Objective)

'The focus of Primomed is the translational medicinal approach of the SMEs, i.e. developing disease modifying therapeutics for high unmet medical needs in chronic inflammatory and degenerative disorders. The Primomed project utilizes well characterized non-human primate models so that the SMEs can capitalize on subsequent clinical successes of their therapeutic lead compounds. The main objectives of the project are (1) to demonstrate proof of concept that drug compounds of the SME’s are efficacious in primate models relevant for the diseases of interest and (2) to determine the immune responses in biological samples generated by the research activities in the different animal models. The power of the Primomed project is the creation of a consortium bringing together four small and early-stage biotech companies owning innovative and proprietary drugs and two of the most renowned European primate research centres that will perform research activities with the new disease modifying molecules of the SME’s. The disease areas of interest in Primomed are asthma, multiple sclerosis and Parkinson disease. Amakem’s Localized Drug Action approach would allow the use of ROCK inhibitors for the treatment of respiratory diseases, e.g. asthma, while avoiding the side effects resulting from systemic ROCK inhibition. By selectively targeting IL-23p19, Complix’ Alphabody is an intriguing candidate for therapy development of asthma and MS and may avoid some of the severe side effects of other currently available and tested anti-IL12/IL23p40 therapies. FFP’s PG102 would be a first in class molecule with a novel mechanism of action in treating chronic inflammatory conditions such as MS. sNRG would be a protein drug with disease modifying potential for the treatment of an unmet medical need in Parkinson’s disease. Primomed will result in progressing the compounds to the clinic, maximize the chance at eventual market authorization and answer the unmet medical need of millions of patients.'

Altri progetti dello stesso programma (FP7-SME)

3FLEX (2013)

Depth enabled workflow for flexible 2D and multiview video production

Read More  

RPC-HVTS-DCS (2009)

Development environment and demonstrators for resonant power conversion facilitating high voltage test systems using very low frequency and DC-sources

Read More  

OPTIMIZR (2013)

ONLINE ANALYSIS TOOL FOR THE OPTIMIZATION OF SOCIAL MEDIA CAMPAIGNS

Read More